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Objectives: Coxsackievirus A group 16 strain (CVA16) is one of the predominant
causative agents of hand, foot, and mouth disease (HFMD).
Methods: Using a specimen from a male patient with HFMD, we isolated and
performed sequencing of the Korean CVA16 strain and compared it with a G10
reference strain. Also, wewere investigated the effects of medicinal plant extract
on the cytopathic effects (CPE) by CPE reduction assay against Korean CVA16.
Results: Phylogenetic analysis showed that the Korean CVA16 isolate belonged to
cluster B-1 and was closely related to the strain PM-15765-00 isolated in Malaysia in
2000. The Korean CVA16 isolate showed 73.2% nucleotide identity to the G10 pro-
totype strain and 98.7% nucleotide identity to PM-15765-00. Next, we assessed
whether the Korean CVA16 isolate could be used for in vitro screening of antiviral
agents to treat HFMD infection. Vero cells infected with the Korean CVA16 isolate
showedacytopathiceffect2days after the infection, and the treatmentofcellswith
Cornus officinalis, Acer triflorum, Pulsatilla koreana, and Clematis heracleifolia
var. davidiana Hemsl extracts exhibited strong antiviral activity against CVA16.
Conclusion: Collectively, our work provides potential candidates for the devel-
opment of vaccine and novel drugs to treat the CVA16 strain isolated from a
Korean patient.), hjko@kangwon.ac.kr (H.-J. Ko).
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A new Coxackievirus A16 strain and its use for drug screening 531. Introduction
CoxsackievirusA16 (CVA16) is a serotype of the genus
Enterovirus belonging to the family Picornaviridae, and
one of the causative agents of hand, foot, and mouth dis-
ease (HFMD) in humans. In rare instances, it may cause
neurological diseases, including aseptic meningitis, exan-
thems, and herpangina. HFMD is a self-limiting exan-
thematous eruption characterized by vesicles in the oral
cavity and peripherally distributed cutaneous lesions on
the hands and feet [1,2]. Recently, large outbreaks of
HFMD by CVA16 and enterovirus 71 (EV71) were re-
ported, especially in the AsiaePacific area [3,4]. Out-
breaks of HFMD by CVA16 occurred in Taiwan
(1996e2006) and in Singapore (2001e2007), as well as in
England (1994) [1,5]. In Korea, outbreaks of HFMD
caused by human enterovirus (HEV) infections have been
consistently reported since 2009 [6e8]. HFMD has
become a serious public health problem in South-East
Asia, with periodic large epidemics occurring in recent
decades.Most of therapeutic and vaccine strategies against
HFMD have focused on EV71 [9,10]. In China, Phase III
trials of antiviral vaccines against EV71 were recently
successfully completed [11]. In addition, no HEV-specific
antiviral drugs are yet available for clinical use. Many
synthetic anti-HEV compounds have been described
in vitro, but only a few of themare effective in vivo [12,13].
However, no vaccines are currently available to prevent
CVA16 infections. Thus, research and development of
vaccines and antiviral drugs to prevent CVA16 infections
and treat HFMD must be spurred on.
A suitable alternative to antiviral drugs may be
traditional medicinal plants. They have multiple targets,
minimal side effects, low potential to cause resistance,
and are less expensive. Screening of medicinal plants
has led to the discovery of potent in vitro inhibitors of
viral replication [14,15].
In this study, the molecular biological characteristics
and genetic diversity of a Korean isolate of CVA16 were
analyzed through complete nucleotide sequencing and
phylogenetic analysis, respectively. Finally, Korean
medicinal plants were screened for their potential anti-
CVA16 effects.2. Materials and methods
2.1. Virus isolation and identification
The Korean CVA16 strain was isolated from the stool
sample of a male patient with HFMD admitted to the
Department of Pediatrics at the Soonchunhyang Uni-
versity Cheonan Hospital, Cheonan, Korea, in June
2008. This study was conducted in accordance with the
ethical principles adopted by the World Medical Asso-
ciation Declaration of Helsinki and approved by the
Institutional Review Board (IRB No. 2012-48) of the
ethical committee of Soonchunhyang UniversityCheonan Hospital. The pretreated sample was inocu-
lated into Vero cells and incubated at 37C in an at-
mosphere of 5% CO2 until the appearance of cytopathic
effects (CPE). Basic Local Alignment Search Tool
(BLAST) search of VP1 sequences verified the identity
of the Korean isolate. The VP1 sequences of the Korean
isolate had the maximum nucleotide similarity with
CVA16 serotype strains [16].
2.2. Nucleotide sequencing and sequence
analysis
The complete nucleotide sequence of the Korean
CVA16 strain was determined using a primer walking
strategy; the sequences of the genome termini were
determined by random amplification of cDNA ends
system (Invitrogen, Carlsbad, CA, USA). Polymerase
chain reaction (PCR) products were purified using a
QIAquick PCR Purification Kit (Qiagen, Hamburg,
Germany). The purified DNA was added to a reaction
mixture containing 2 mL of BigDye terminator reaction
mix (ABI Prism BigDye Terminator Cycle Sequencing
Kit; Applied Biosystems, Foster, CA, USA) and 2 pmol
of each primer. Sequencing reactions were subjected to
an initial denaturation at 96C for 1 minute and 25 cy-
cles consisting of 96C for 10 seconds, 50C for 5
seconds, and 60C for 4 minutes in a Gene Amp PCR
system 2700 (Applied Biosystems). The products were
purified by precipitation with 100% cold ethanol and 3M
sodium acetate (pH 5.8), and then loaded on an auto-
mated 3100 Genetic Analyzer (Applied Biosystems).
Nucleotide sequences of CVA 16 strains were con-
structed to contig and compared with the reference G10
strain (accession no. U05876). G10 strain, obtained from
Genbank databases, was isolated in South Africa in 1954
and subsequently sequenced in 1994 [17,18]. The
complete sequences of the Korean CVA16 isolate are
deposited in the GenBank sequence database under the
accession number JX839965. Complete nucleotide se-
quences of CVA16 isolate were compared with the
reference strains by using CLUSTAL W (version 1.81)
[19]. The phylogenetic relationships of each virus
isolate were inferred using free MEGA software
version 5.05 (Available from www.megasoft.net). The
maximum composite likelihood method was used as the
substitution method, while the neighbor-joining method
was used to reconstruct the phylogenetic tree [20]. The
reliability of the phylogenetic tree was determined by
bootstrap resampling of 1000 replicates.
2.3. High-throughput screening of medicinal
plant extracts for antiviral activity against
CVA16
A medicinal plant extract library was supplied by the
Ginseng Research Division, National Institute of
Horticultural and Herbal Science, Eumseong-gun,
Chungcheongbuk-do, Korea. To screen 492 medicinal
54 J.-H. Song, et alplant extracts, Vero cells were seeded in 96-well plates.
After CVA16 infection, the plates were incubated with
individual plant extract at 10 mg/mL for 48 hours. The
antiviral activity was measured using a sulforhodamine
B (SRB) assay.
2.4. Antiviral activity and cytotoxicity assays
Antiviral activity and cytotoxicity were evaluated by
the SRB method using CPE reduction recently reported
[21]. The effect of Cornus officinalis, Acer triflorum,
Pulsatilla koreana, and Clematis heracleifolia var.
davidiana extracts on CVA16-induced CPE was
observed. Briefly, Vero cells were seeded onto a 96-well
culture plate at a concentration of 2  104 cells/well.
Next day, the medium was removed and washed with
phosphate-buffered saline. Then, 0.09 mL of diluted
virus suspension and 0.01 mL of the medium supple-
mented with FBS containing 0.4 mg/mL, 2 mg/mL,
10 mg/mL, and 50 mg/mL C. officinalis, A. triflorum, P.
koreana, or C. heracleifolia var. davidiana Hemsl were
added. After incubation at 37C in 5% CO2 for 2 days,
cell morphology was microscopically observed at
4  10 magnification (Axiovert10, Zeiss, Germany), and
images were recorded. Cytotoxicity was measured by
the antiviral activity assay as described above. To
calculate the concentration required to reduce cell
growth by 50% (CC50) values, the data were expressed
as percentages relative to controls, and CC50 values
were obtained from the resulting dose-response curves.
2.5. Real-time reverse transcription-PCR
Total RNA was isolated from Vero cells. Reverse
transcription was performed using SuperScript II Reverse
Transcriptase (Invitrogen, Grand Island, NY, USA) ac-
cording to the manufacturer’s instructions. For real-time
PCR analysis, the cDNA was serially diluted 10-fold and
amplified using the 7500 Real Time PCR System
(Applied Biosystems, Grand Island, NY, USA) with
Power SYBR Green PCR Master Mix (Applied Bio-
systems). After the first denaturation step (95C for 10
minutes), amplification was performed for 40 cycles at
95C for 15 seconds, 55C for 15 seconds, and 72C for
40 seconds. The final cycle was followed by the disso-
ciation stage. The following primers were used: 50 NCR
gene, 50-CCG GCC CCT GAA TGC GG-30 and 50-ATT
CTT TAA TTG TCA CCA TAA GCA GCC A-30 and b-
actin gene, 50-CAA TCA TGA AGT GTG ACG TGG-30
and 50-GTC CGC CTA GAA GCA TTT GCG-30.
2.6. Statistical analyses
Differences across more than three groups are
analyzed using one-way Analysis of Variance
(ANOVA) (Graphpad P, version 5.01). All results were
expressed as means  standard deviation. Significant
differences in direct comparisons were determined using
Tukey’s post hoc test. Differences with p < 0.05 were
considered statistically significant.3. Results
3.1. Analysis of nucleotide sequence of Korean
CVA 16
The complete sequences of the Korean CVA16
isolate are deposited in the GenBank sequence database
under the accession number JX839965. The genome is
7,411 nt in length, excluding the poly(A) tail. The
50NCR contains 745 nt, followed by an ORF that en-
codes a viral polyprotein consisting of 2,194 codons,
between a start codon (AUG) at position 746 and a stop
codon (UGA) at position 7,327. The 30NCR is 84 nt in
length. These nucleotide sequences were used to
construct a phylogenetic tree with 39 reference strains of
the same serotype extracted from GenBank database.
The CVA16 strains including Korean CVA16 isolate
were segregated into four distinct genetic groups, which
were supported by high bootstrap values (Figure 1). In
phylogenetic relationships, the Korean CVA16 isolate
belonged to cluster B-1 and was closely related to strain
PM-15765-00 isolated in Malaysia in 2000. The Korean
CVA16 isolate showed 73.2% nucleotide identity to the
G10 prototype strain and 98.7% nucleotide identity to
the PM-15765-00 strain.
3.2. Identification of antiviral activity of four
medicinal plant extract against CVA16
We sought to identify the antiviral activity of me-
dicinal plant extracts against CVA16. Four extracts were
identified from 492 medicinal plant extracts screened
that showed significant cell viability of > 50%, indi-
cating antiviral activity against CVA16 (data not
shown). The four extracts are C. officinalis, A. triflorum,
P. koreana, and C. heracleifolia var. davidiana Hemsl.
3.3. Antiviral activity of four medicinal plant
extracts against CVA16
To determine drug potency, CVA16-infected Vero
cells were treated with various doses of the four me-
dicinal plant extracts. The antiviral assays demonstrated
that P. koreana and C. heracleifolia var. davidiana
Hemsl possessed strong antiviral activity of > 60%
against CVA16 at concentrations of 2 mg/mL, 10 mg/mL,
and 50 mg/mL. C. officinalis and A. triflorum showed
80% and 70% antiviral activity, respectively, against
CVA16 at the concentration of 50 mg/mL (Figure 2A).
The values of concentration required to inhibit virus-
induced cytopathic effects by 50% were 32.9 mg/mL,
32.3 mg/mL, 1.51 mg/mL, and 2.55 mg/mL for C. offi-
cinalis, A. triflorum, P. koreana, and C. heracleifolia
var. davidiana Hemsl extract, respectively. The CC50
values of C. officinalis, A. triflorum, P. koreana, and C.
heracleifolia var. davidiana Hemsl extracts were supe-
rior to 50 mg/mL (Table 1). In addition, we confirmed
the antiviral activity of the four medicinal plant extracts
against CVA16 by real-time PCR analysis. The highest
Figure 1. Phylogenetic analysis based on full-length genomic sequences of a CVA16 isolate from a patient with hand, foot, and
mouth disease. Nucleotide sequences were analyzed by the neighbor-joining method. The numbers at the branches indicate the
bootstrap values for 1000.
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mL for the C. officinalis and A. triflorum extracts, while
the P. koreana and C. heracleifolia var. davidiana
Hemsl extracts inhibited CVA16 replication only
marginally at all concentrations (Figure 2B).
3.4. The effect of four medicinal plant extracts
on CVA16 virus-induced CPE
After Day 2 post infection with CVA16, there was no
difference between mock or Vero cells treated with
50 mg/mL of C. officinalis, A. triflorum, P. koreana, or
C. heracleifolia var. davidiana Hemsl, in terms of
typical spread-out shapes and normal morphology.
Infection of Vero cells with CVA16 resulted in a severeCPE, whereas CVA16-infected Vero cells treated with
the medicinal plant extracts exhibited noticeably
reduced CPE compared with untreated CVA16-infected
cells (Figure 3). These results indicate that the CPE of
CVA16 infection is prevented by C. officinalis, A. tri-
florum, P. koreana, or C. heracleifolia var. davidiana
Hemsl.4. Discussion
CVA16 and EV71 infections are both responsible for
widespread HFMD and present serious public health
problems in the AsiaePacific region [22,23]. However,
Figure 2. Antiviral activity of medicinal plant extracts
against CVA16 in Vero cells. (A) Vero cells were infected
with CVA16 and treated with the indicated concentrations
(0.4e50 mg/mL) of medicinal plant extracts for 48 hours.
Antiviral activity was assessed using a cytopathic effects
reduction assay. Results are presented as the mean percentage
values obtained from three independent experiments carried
out in triplicate  standard deviation. (B) Vero cells were
infected with CVA16 and treated with various concentrations
of Cornus officinalis, Acer triflorum, Pulsatilla koreana, and
Clematis heracleifolia var. davidiana Hemsl for 48 hours.
CVA16 50NCR genes were quantitatively measured using real-
time reverse transcription polymerase chain reaction.
56 J.-H. Song, et althere are no available therapeutics to treat CVA16 or
EV71 infections effectively. Most of antiviral and vac-
cine studies have been focusing on EV71, since it was
reported to be associated with severe complications
involving neuropathological complications and signifi-
cant mortality [24,25]. However, evidence has shown
that CVA16 infection also causes severe neurological
complications and death [26,27], and HFMD caused byTable 1. Antiviral activity of four medicinal plant ex-
tracts against CVA16.
Medicinal plant extract
Coxsackievirus A16
CC50 IC50 TI
Cornus officinalis > 50 32.9  1.30 1.52
Acer triflorum > 50 32.3  1.67 1.55
Pulsatilla koreana > 50 1.51  0.05 33.11
Clematis heracleifolia
var. davidiana Hemsl
> 50 2.55  1.06 19.61
Results are presented as the mean IC50 values  standard deviation
obtained from three independent experiments carried out in triplicate.
CC50Z concentration required to reduce cell growth by 50% (mg/mL);
IC50 Z concentration required to inhibit virus-induced cytopathic ef-
fects by 50% (mg/mL); TI Z therapeutic index Z CC50/IC50.CVA16 is now considered as a serious public health
threat in young children, especially in the AsiaePacific
region. In the current study, the first complete nucleotide
sequence of a CVA16 isolate from a HFMD patient in
Korea was described and its genetic diversity explored
by phylogenetic analysis against 39 reference strains. In
addition, a Korean medicinal plant library of 492 ex-
tracts was screened to find candidates with antiviral
properties against the Korean CVA16 isolate.
CVA16 usually has a high mutation rate during viral
replication due to the deficiency of proofreading activity
[28], and there was > 20% genetic difference between
G10 prototype strain and the current widespread strain.
Therefore, it would be difficult to develop a therapeutic
antiviral drug against the current epidemic strain [29]. In
the current study, we isolated a CVA16 from Korean
HFMD patients, and confirmed that the CVA16 isolate
could be used for development and screening of antiviral
drugs in vitro.
Many plant-derived natural products have been used
in traditional medicine for the treatment of various
diseases, including viral infection. In the current study,
we found that CVA16 infection in Vero cells could be
prevented by extract of C. officinalis, A. triflorum, P.
koreana, or C. heracleifolia var. davidiana Hemsl.
Among them, C. officinalis is a species of dogwood and
a known edible plant. Particularly, the fruit of C. offi-
cinalis is well known for its chemotherapeutic benefits.
Recently, cornuside, isolated from the fruit of C. offi-
cinalis, was reported to have anti-inflammatory activity
by inhibiting tumor necrosis factor-a production [30].
Cornuside has also been reported to inhibit
lipopolysaccharide-induced inflammation by inhibiting
nuclear factor-kB pathway [31]. Next, P. koreana is a
perennial plant found in South Korea, and its roots have
been used as traditional medicine for the treatment of
dysentery, malaria, chills, and fever [32]. In addition,
previous studies suggested that it has antifungal and
antibiotic properties and antitumor effects and that it can
lower blood pressure [33,34]. Unlike C. officinalis and
P. koreana, there are few reports regarding the biolog-
ical activities or medical uses of A. triflorum and C.
heracleifolia var. davidiana Hemsl. More interestingly,
there are no reports suggesting an antiviral activity of
the C. officinalis, A. triflorum, P. koreana, or C. her-
acleifolia var. davidiana Hemsl extracts, and thus,
further studies to elucidate the antiviral constituents of
those plants are needed.
In this study, the CC50 values of all extracts were >
50 mg/mL, suggesting that the extracts of those plants
are nontoxic to Vero cells even in high concentrations.
In addition, when their antiviral activities were assessed
after CVA16 infection, all of the extracts showed sig-
nificant antiviral activity against the Korean CVA16
isolate. In particular, C. officinalis and A. triflorum
revealed high suppression potency against viral gene
replication as assessed by real-time PCR, which
Figure 3. Morphological assessment of CVA16-infected Vero cells following treatment with four medicinal plant extracts.
CVA16-infected and uninfected Vero cells were treated with 50 mg/mL medicinal plant extracts. After staining of viable cells with
sulforhodamine B, cell morphology was assessed by microscopy. (A) Untreated, (B) uninfected cells treated with Cornus offici-
nalis, (C) Acer triflorum, (D) Pulsatilla koreana, (E) Clematis heracleifolia var. davidiana Hemsl, (F) untreated CVA16-infected
cells, (G) CVA16-infected cells treated with Cornus officinalis, (H) CVa16-infected cells treated with Acer triflorum, (I) CVA16-
infected cells treated with Pulsatilla koreana, and (J) CVA16-infected cells treated with Clematis heracleifolia var. davidiana
Hemsl.
A new Coxackievirus A16 strain and its use for drug screening 57correlates with their antiviral activity tested by SRB
assay. Although the extracts of P. koreana and C. her-
acleifolia var. davidiana Hemsl also showed high anti-
viral activity, their suppressive ability on viral
replication was moderate.
In conclusion, this study is the first report of the
complete nucleotide sequence of the Korean CVA16,
and shows the possibility of using the virus for the
screening of antiviral drug candidates against HFDM
infection in Korea. Antiviral activity screening of 492
medicinal plant extracts showed that C. officinalis, A.
triflorum, P. koreana, and C. heracleifolia var. davidi-
ana Hemsl possessed strong antiviral activity against
this Korean CVA16 isolate. The data would be useful in
preventing future outbreaks of CVA16 and in treating
patients infected with the strain. Prospectively, identi-
fication of antiviral constituents included in the medic-
inal plant extracts and study of the mechanisms
underlying their antiviral activity is necessary for the
development of antiviral therapeutics to treat Korean
HFDM patients infected with CVA16.Conflicts of interest
All contributing authors declare no conflicts of
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